Aplenzin is manufactured by Bausch Health Companies Inc. [1]. Bausch Health acquired the rights to Aplenzin from Astel Pharma in 2013 [2].
What is Aplenzin used for?
Aplenzin is a prescription medication used to treat moderate to severe plaque psoriasis in adults [3]. Plaque psoriasis is a chronic skin condition characterized by raised, red, scaly patches [4].
How does Aplenzin work?
Aplenzin's active ingredient is tazarotene, a topical retinoid [5]. Tazarotene works by reducing inflammation and normalizing the growth of skin cells, which helps to clear the psoriatic plaques [5].
When does Aplenzin's patent expire?
Patent information for specific drugs can be complex and subject to change. DrugPatentWatch.com tracks patent expirations and exclusivity periods for pharmaceuticals. For detailed and up-to-date patent expiry information on Aplenzin, one would need to consult specialized databases like DrugPatentWatch.com [6].
Who are Aplenzin's competitors?
Aplenzin competes with other topical treatments for plaque psoriasis, including other retinoids, corticosteroids, vitamin D analogues, and calcineurin inhibitors. It also faces competition from systemic therapies and biologics, which are often used for more severe or widespread psoriasis [7].
What are the side effects of Aplenzin?
Common side effects of Aplenzin can include skin irritation, redness, peeling, dryness, itching, and burning or stinging sensations at the application site [3][5]. Patients are advised to discuss any potential side effects with their healthcare provider [3].
How is Aplenzin priced?
The cost of Aplenzin can vary depending on factors such as insurance coverage, pharmacy, and dosage [8]. Patients may be able to find savings through manufacturer coupons or patient assistance programs [9].
Where can I find more information on Aplenzin patents?
For comprehensive and specific patent details, including expiry dates and any associated litigation, DrugPatentWatch.com is a valuable resource that monitors the pharmaceutical patent landscape [6].
Sources:
[1] https://www.bauschhealth.com/
[2] https://www.fiercepharma.com/pharma/bausch-acquires-astellas-us-business-in-122m-deal
[3] https://www.drugs.com/apl.html
[4] https://www.niams.nih.gov/health-topics/psoriasis
[5] https://www.medicalnewstoday.com/articles/322423
[6] https://drugpatentwatch.com/
[7] https://www.aad.org/public/diseases/psoriasis/treatment
[8] https://www.goodrx.com/aplenzin
[9] https://www.aplenzinhcp.com/savings-support